VDRA therapy is associated with improved survival in dialysis patients with serum intact PTH ≤150 pg/mL: Results of the Italian FARO Survey

Nephrology Dialysis Transplantation

Volumn 27, Issue 9, 2012, Pages 3588-3594

  Cozzolino, Mario ^a   Brancaccio, Diego ^b   Cannella, Giuseppe ^c   Messa, Piergiorgio ^d   Gesualdo, Loreto ^e   Marangella, Martino ^f   Lodeserto, Cosimo ^g   Pozzato, Marco ^h   Rombolà, Giuseppe ⁱ   Costanzo, Anna Maria ^j   Di Luzio Paparatti, Umberto ^j   Mazzaferro, Sandro ^k  

^a UNIVERSITY OF MILAN   (Italy)

^b Simone Martini   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^e UNIVERSITY OF BARI   (Italy)

^f MAURIZIANO HOSPITAL   (Italy)

^g Hospital of Taranto   (Italy)

^h S GIOVANNI BOSCO HOSPITAL   (Italy)

ⁱ SAPIENZA UNIVERSITY OF ROME   (Italy)

^j ABBOTT DIAGNOSTICS   (Italy)

^k SAPIENZA UNIVERSITY OF ROME   (Italy)

more..

Author keywords

calcitriol; CKD MBD; haemodialysis; paricalcitol; PTH

Indexed keywords

CALCITRIOL; PARATHYROID HORMONE; PARICALCITOL; PHOSPHATE BINDING AGENT;

ADULT; AGED; ARTICLE; BONE MINERALIZATION; CHRONIC KIDNEY DISEASE; DEATH; DEMOGRAPHY; FEMALE; HEALTH SURVEY; HEMODIALYSIS; HEMODIALYSIS PATIENT; HIGH RISK POPULATION; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; METABOLIC BONE DISEASE; MORTALITY; NORMAL VALUE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PARATHYROID HORMONE BLOOD LEVEL; PRIORITY JOURNAL; PROBABILITY; PROSPECTIVE STUDY; SURVIVAL; TIME TO DEATH; TREATMENT DURATION;

AGED; BONE DENSITY CONSERVATION AGENTS; BONE DISEASES; CALCIFICATION, PHYSIOLOGIC; ERGOCALCIFEROLS; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HEALTH SURVEYS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PARATHYROID HORMONE; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTORS, CALCITRIOL; RENAL DIALYSIS; SURVIVAL RATE;

EID: 84864487383     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfs108     Document Type: Article

References (40)

1. Andress DL. Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor activation. Kidney Int 2006; 69: 33-43.
2. Martin KJ, Gonzalez EA. Metabolic bone disease in chronic kidney disease. J Am Soc Nephrol 2007; 18: 875-885.
3. Cozzolino M, Ketteler M, Zehnder D. The vitamin D system: a crosstalk between the heart and kidney. Eur J Heart Fail 2010; 12: 1031-1041.
4. Dusso AS, Brown AJ, Slatopolsky E. Vitamin D. Am J Physiol Renal Physiol 2005; 289: F8-28.
5. Salusky IB, Goodman WG. Cardiovascular calcification in end-stage renal disease. Nephrol Dial Transplant 2002; 17: 336-339.
6. Wolisi GO, Moe SM. The role of vitamin D in vascular calcification in chronic kidney disease. Semin Dial 2005; 18: 307-314.
7. Brown AJ, Slatopolsky E. Drug insight: vitamin D analogs in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease. Nat Clin Pract Endocrinol Metab 2007; 3: 134-144.
8. Ronco C, Cozzolino M. Mineral metabolism abnormalities and vitamin D receptor activation in cardiorenal syndromes. Heart Fail Rev 2011; doi:10.1007/s10741-011-9232-8.
9. Cozzolino M, Brandenburg V. Paricalcitol and outcome: a manual on how a vitamin D receptor activator (VDRA) can help us to get down the "U". Clin Nephrol 2009; 71: 593-601.
10. Khan S. Vitamin D deficiency and secondary hyperparathyroidism among patients with chronic kidney disease. Am J Med Sci 2007; 333: 201-207.
11. Cozzolino M, Gallieni M, Pasho S et al. Management of secondary hyperparathyroidism in the elderly patient with chronic kidney disease. Drugs Aging 2009; 26: 457-468.
12. Kalantar-Zadeh K, Kuwae N, Regidor DL et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006; 70: 771-780.
13. Teng M, Wolf M, Ofsthun MN et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005; 16: 1115-1125.
14. Tentori F, Hunt WC, Stidley CA et al. Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int 2006; 70: 1858-1865.
15. Naves-Díaz M, Alvarez-Hernández D, Passlick-Deetjen J et al. Oral active vitamin D is associated with improved survival in hemodialysis patients. Kidney Int 2008; 74: 1070-1078.
16. Wolf M, Thadhani R. Vitamin D in patients with renal failure: a summary of observational mortality studies and steps moving forward. J Steroid Biochem Mol Biol 2007; 103: 487-490.
17. Andress D. Nonclassical aspects of differential vitamin D receptor activation: implications for survival in patients with chronic kidney disease. Drugs 2007; 67: 1999-2012.
18. Levin A, Bakris GL, Molitch M et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 2007; 71: 31-38.
19. Guideline Working Group, Japanese Society for Dialysis Therapy. Clinical practice guideline for the management of secondary hyperparathyroidism in chronic dialysis patients. Ther Apher Dial 2008; 12: 514-525.
20. Nakai S, Akiba T, Kazama J et al. Effects of serum calcium, phosphorous, and intact parathyroid hormone levels on survival in chronic hemodialysis patients in Japan. Ther Apher Dial 2010; 12: 49-54.
21. Naves-Díaz M, Passlick-Deetjen J, Guinsburg A et al. Calcium, phosphorus, PTH and death rates in a large sample of dialysis patients from Latin America. The CORES Study. Nephrol Dial Transplant 2011; 26: 1938-1947.
22. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42: S1-S202.
23. Couttenye MM, D'Haese PC, Deng JT et al. High prevalence of adynamic bone disease diagnosed by biochemical markers in a wide sample of the European CAPD population. Nephrol Dial Transplant 2008; 12: 2144-2150.
24. Salusky IB, Ramirez JA, Oppenheim Wet al. Biochemical markers of renal osteodystrophy in pediatric patients undergoing CAPD/CCPD. Kidney Int 1994; 45: 253-258.
25. Wolf M, Shah A, Gutierrez O et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 2007; 72: 1004-1013.
26. Wolf M, Betancourt J, Chang Y et al. Impact of activated vitamin D and race on survival among hemodialysis patients. J Am Soc Nephrol 2008; 19: 1379-1388.
27. Kovesdy CP, Ahmadzadeh S, Anderson JE et al. Association of activated vitamin D treatment and mortality in chronic kidney disease. Arch Intern Med 2008; 168: 397-403.
28. Shoben AB, Rudser KD, de Boer IH et al. Association of oral calcitriol with improved survival in nondialyzed CKD. J Am Soc Nephrol 2008; 19: 1613-1619.
29. Mazzaferro S, Brancaccio D, Messa P et al. Management of secondary hyperparathyroidism in Italy: results of the Italian FARO survey. J Nephrol 2011; 24: 225-235.
30. Floege J, Kim J, Ireland E et al. Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Nephrol Dial Transplant 2011; 26: 1948-1955.
31. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int 2009; 76 (Suppl 113): S1-S130.
32. Brancaccio D, Cozzolino M, Cannella G et al. Secondary hyperparathyroidism in chronic dialysis patients: results of the Italian FARO survey on treatment and mortality. Blood Purif 2011; 32: 124-132.
33. Teng M, Wolf M, Lowrie E et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003; 349: 446-456.
34. Tentori F, Albert JM, Young EW et al. The survival advantage for haemodialysis patients taking vitamin D is questioned: findings from the Dialysis Outcomes and Practice Patterns Study. Nephrol Dial Transplant 2009; 24: 963-972.
35. Tentori F, Blayney MJ, Albert JM et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2008; 52: 519-530.
36. Guh JY, Chen HC, Chuang HY et al. Risk factors and risk for mortality of mild hypoparathyroidism in hemodialysis patients. Am J Kidney Dis 2002; 39: 1245-1254.
37. Shinaberger CS, Kopple JD, Kovesdy CP et al. Ratio of paricalcitol dosage to serum parathyroid hormone level and survival in maintenance hemodialysis patients. Clin J Am Soc Nephrol 2008; 3: 1769-1776.
38. Salas M, Hofman A, Stricker BH. Confounding by indication: an example of variation in the use of epidemiologic terminology. Am J Epidemiol 1999; 149: 981-983.
39. Cantor T. Parathyroid hormone assay drift: an unappreciated problem in dialysis patient management. Semin Dial 2005; 18: 359-364.
40. Sturgeon CM, Sprague SM, Metcalfe W. Variation in parathyroid hormone immunoassay results-a critical governance issue in the management of chronic kidney disease. Nephrol Dial Transplant 2011; 26: 3440-3445.